We are back from the Phacilitate Cell & Gene Therapy Forum 2009 and we've captured some highlights, which include Lee Buckler's review, some great interviews, brand new Mash Ups, and 60sec Pitches. Take a look!
The BioBusiness.TV Team.
Lee Buckler's Cell Therapy '08 Review and '09 Outlook.
Some of the exciting things we've seen in 2008 are:
- the involvement of pharma in cell therapy, investing like they haven't before, developing cell therapy products as drugs, and not just tools (including companies such as Pfizer, GSK, Roche, and Novartis)
- the number of late stage companies in the sector such as Osiris (see: Osteocel / NuVasis, and Prochymal + Chondrogen / Genzyme deals), Dendreon, and others
- the financing, partnerships and M&A activity with $400M private equity investment, $100M M&A, and $1.8bn in non-M&A deals.
- some of the late stage companies (Osiris and Dendrion - i.e. Provenge results in April)
- the struggling cell therapy companies and how they will find cash (M&A, Government, VC?)
- the role of the new Obama administration and the public pressure, interest, and enthusiasm for cell therapy.
_____________Harvard Steps Into the Cell Therapy Funding Gap with a Mission for Academic Research to Get to Patients.
Brock Reeve explains the functioning of the Harvard Stem Cell Institute (HSCI). The HSCI is looking to make the bedside-to-bench and bench-to-bench loop in a way that is unequaled anywhere, with the university and its 11 affiliated hospitals, drawing resources from the various schools (law, business, government, divinity). Brock tell us about about the HSCI partnership with GSK, as well as the other relationships they are seeking and building at the moment.
Watch Program »
_____________Roche's Vertes on Big Pharma's Interest in Cell Therapy.Alain Vertes of Roche presents the interest of his company in the cell therapy. He highlights the main points of his panel presentation:
1. Cell therapy is not a passing fad
2. Cell are not just transplants, they can also be drugs
3. Paradigm shifting applications for cell therapy
4. Protecting intellectual property
5. Potential for stunning efficacy and low risk of side effects.
Watch Program »
_____________US and EU Regulatory Synergies, and EMEA Committee for Advanced Therapies.
Christopher Bravery comments on the new committee for advanced therapies of the EMEA, and its impact on the development of cell therapy in Europe. Christopher also reflects on the similarity between US and European regulatory environments, and the importance of considering that in planning pivotal studies. He also gives us his definition of Cell Therapy and explains the business of ERA Consulting.
Watch Program »
_____________'Mash UP'. Delegate responses to the following questions:
- How Would You Define Cell Therapy?
- Are We Going to See New Cell Therapy Products in the Next 2-3 Years?
- How Many Cell Therapy Products Are On the Market Today?
- What Are Some of the Exciting Things Happening in Cell Therapy?
Interested in your company sponsoring future content like this focusing on the cell therapy market for BioBusiness.TV? Interested in sponsoring a cell therapy "channel" on the site? Contact Lee Buckler @ [the] Cell Therapy Group.